Newron Can't Get Parkinson's Drug Patent Widened On Appeal
Newron Pharmaceuticals can't get additional patent protections for its Parkinson's treatment Xadago, the Court of Appeal ruled Thursday, rejecting Newron's assertion that judges failed to properly distinguish between the formula and...To view the full article, register now.
Already a subscriber? Click here to view full article